- Home
- SLS vs NVCT Comparison
SLS vs NVCT Comparison
Compare SLS & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- NVCT
- Stock Information
- Founded
- SLS 2012
- NVCT 2020
- Country
- SLS United States
- NVCT United States
- Employees
- SLS N/A
- NVCT N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- SLS Health Care
- NVCT Health Care
- Exchange
- SLS Nasdaq
- NVCT Nasdaq
- Market Cap
- SLS 169.6M
- NVCT 184.9M
- IPO Year
- SLS N/A
- NVCT 2022
- Fundamental
- Price
- SLS $1.54
- NVCT $8.13
- Analyst Decision
- SLS
- NVCT Strong Buy
- Analyst Count
- SLS 0
- NVCT 3
- Target Price
- SLS N/A
- NVCT $17.00
- AVG Volume (30 Days)
- SLS 2.6M
- NVCT 97.5K
- Earning Date
- SLS 08-12-2025
- NVCT 08-05-2025
- Dividend Yield
- SLS N/A
- NVCT N/A
- EPS Growth
- SLS N/A
- NVCT N/A
- EPS
- SLS N/A
- NVCT N/A
- Revenue
- SLS N/A
- NVCT N/A
- Revenue This Year
- SLS N/A
- NVCT N/A
- Revenue Next Year
- SLS N/A
- NVCT N/A
- P/E Ratio
- SLS N/A
- NVCT N/A
- Revenue Growth
- SLS N/A
- NVCT N/A
- 52 Week Low
- SLS $0.77
- NVCT $4.44
- 52 Week High
- SLS $2.12
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- SLS 45.96
- NVCT 37.24
- Support Level
- SLS $1.47
- NVCT $8.79
- Resistance Level
- SLS $1.73
- NVCT $9.30
- Average True Range (ATR)
- SLS 0.11
- NVCT 0.50
- MACD
- SLS -0.02
- NVCT -0.11
- Stochastic Oscillator
- SLS 19.44
- NVCT 12.43
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.